Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC MSB11456

In the graph: all 5 documents (10 pages).

Application: NDA 214610
Ticker: Fresenius Kabi USA, LLC
Product: MSB11456
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: February 27, 2026 · February 27, 2026 · April 25, 2025 · December 11, 2024 · May 31, 2023

From FDA letters and SEC filings. Not investment or medical advice.

Dr. Reddy’s Laboratories, Inc. AVT03
DURECT Corporation POSIMIR
Eagle Pharmaceuticals, Inc. Fulvestrant
ELC Group Lutrate®
Elevar Therapeutics, Inc. rivoceranib
Eli Lilly and Company lebrikizumab
EMD Serono, Inc. cladribine
Emory Partners, LLC Dyanavel XR
Esteve Pharmaceuticals, S.A. celecoxib
Evergreen Theragnostics, Inc.
Evofem, Inc. Amphora
Evoke Pharma, Inc. Gimoti
Evolus, Inc. otulinum toxin Type A
Eyenovia, Inc. MYDCOMBI
Fabre-Kramer Pharmaceuticals, Inc. Gepirone Hydrochloride Extended Release
The Feinstein Institute for Medical Research Fluorodopa F
Fennec Pharmaceuticals, Inc. PEDMARK
Fera Pharmaceuticals, LLC Avaclyr
Ferring Pharmaceuticals Inc. progesterone
Fidelity BioPharma Co. Ontralfy
Fresenius Kabi USA, LLC MSB11456
Galderma R&D, LLC this action
Galephar Pharmaceutical Research Inc. Legubeti
Gan & Lee Pharmaceuticals
Genentech, Incorporated XOFLUZA
Genzyme Corporation tolebrutinib
Gilead Sciences, Inc. lenacapavir
GlaxoSmithKline LLC Exdensur lepemokimab-ulaa)
Glenmark Pharmaceuticals, Inc. GSP
Grace Therapeutics U.S., Inc. nimodipine
Green Cross Corporation immune globulin
Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc. the following drug product: > Atazanavir Sulfate
Heron Therapeutics, Inc. Zynrelef
Hikma Pharmaceuticals USA Inc. phenobarbital sodium
Hospira, Inc. Daptomycin
HQ Specialty Pharma Corporation Meropenem
Hugel, Inc letibotulinumtoxinA
Immedica Pharma AB
Immunomedics, Inc sacituzumab govitecan

Group by

Build queue · replay at pipeline speed